Skip to main content
. 2018 Dec 5;17(2):1497–1504. doi: 10.3892/ol.2018.9795

Figure 1.

Figure 1.

Serum CgA levels in 73 patients with naive or recurrent GEP-NENs (Group 1), 36 patients with GEP-NEN cured following surgery (Group 2), 30 healthy controls (Group 3) and 30 patients with other digestive tract diseases (Group 4). There was a statistically significant difference between Group 1 and the other three groups (Groups 2–4). *P<0.05 compared with other groups. CgA, chromogranin A; GEP-NEN, gastroenteropancreatic neuroendocrine neoplasm.